{"filings":[{"id":746559,"accession_number":"0000939767-26-000074","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-05-29T20:05:57+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Exelixis shareholders approve 2017 equity plan amendment, adding 2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2017 Plan, adding 2,000,000 shares to the share reserve.","Full Value Awards granted on or after May 26, 2026, will count as 1 share per share issued (previously 2 for 1).","All 11 director nominees elected; Ernst & Young ratified as auditor; say-on-pay approved.","Amended plan effective immediately upon stockholder approval at May 26, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99924,"accession_number":"0000939767-26-000058","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exelixis Q1 revenue $610.8M, GAAP EPS $0.79; announces $750M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $610.8M (+10% YoY); cabozantinib U.S. net product revenue $555.0M.","GAAP diluted EPS $0.79 (vs. $0.55 in Q1 2025); non-GAAP diluted EPS $0.87.","Board authorized new $750M stock repurchase program through Dec 31, 2027.","Zanzalintinib NDA accepted for colorectal cancer; PDUFA target Dec 3, 2026.","Company plans to complete current $750M buyback this month."],"consensus_eps_estimate":null,"consensus_eps_actual":0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":610812000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116221,"accession_number":"0000939767-26-000019","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q4 revenue $599M, diluted EPS $0.88; cabozantinib franchise up 17% in FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $598.7M vs $566.8M YoY; GAAP diluted EPS $0.88 vs $0.48.","FY2025 net product revenue $2.123B, up from $1.809B, driven by cabozantinib volume growth.","GAAP net income $782.6M in FY2025 ($2.78 diluted EPS); non-GAAP $869.5M ($3.08 diluted EPS).","R&D expenses fell to $825M (down 9.4% YoY); SG&A rose 5.4% to $518.7M.","NDA for zanzalintinib in mCRC accepted; STELLAR-303/304 readouts and trials expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2320126000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116220,"accession_number":"0000939767-26-000003","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis releases preliminary FY2025 results, FY2026 guidance; audit ongoing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Preliminary unaudited FY2025 results announced; specific financial figures not included in filing.","Financial guidance for FY2026 provided; details not disclosed in the exhibit text available.","Business update delivered; audited FY2025 results to be reported on February 10, 2026.","Audit of FY2025 financial statements is ongoing and may change preliminary information."],"consensus_eps_estimate":null,"consensus_eps_actual":2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2320126000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132675,"accession_number":"0000939767-25-000133","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Exelixis GC Jeff Hessekiel resigns; Brenda Hefti promoted to succeed him","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Hessekiel, EVP & General Counsel, resigns effective Nov 2025; ceases role Nov 7.","Resignation not due to any disagreement with the company.","Brenda Hefti, SVP IP & Licensing, promoted to General Counsel effective Nov 7, 2025.","Hefti joined in 2013, became Head of IP in 2014, and SVP since 2020; reports to CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132674,"accession_number":"0000939767-25-000127","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exelixis Q3 revenues $597.8M, EPS $0.69; announces $750M stock buyback by 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $597.8M (+10.8% YoY); cabozantinib US net product rev $542.9M (+13.5% YoY).","GAAP diluted EPS $0.69 (vs $0.40); Non-GAAP diluted EPS $0.78 (vs $0.47).","Board authorized $750M stock repurchase program through Dec 31, 2026.","Restructuring charges $19.8M related to corporate reorganization; plan to close King of Prussia office.","Zanzalintinib NDA submission planned before year-end based on positive STELLAR-303 colorectal cancer data."],"consensus_eps_estimate":null,"consensus_eps_actual":1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1721463000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149195,"accession_number":"0000939767-25-000115","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exelixis appoints Dana Aftab as EVP R&D; Amy Peterson departs as CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dana Aftab, Ph.D., promoted to EVP of R&D effective August 29, 2025; previously EVP Discovery & CSO.","Amy C. Peterson, M.D., concluded service as EVP Product Development and CMO on same date.","Dr. Peterson eligible for severance under Exelixis's Change in Control and Severance Benefit Plan.","No other officer changes disclosed; Dr. Aftab's compensation terms unchanged from prior proxy filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149194,"accession_number":"0000939767-25-000111","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q2 2025: total rev $568M, GAAP EPS $0.65; CABOMETYX NET launch, positive STELLAR-303","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $568.3M; product revenues $520.0M (+19% YoY); collaboration rev $48.2M (down $151M due to prior-year Ipsen milestone).","GAAP net income $184.8M ($0.65 diluted EPS); non-GAAP net income $212.6M ($0.75 diluted EPS).","CABOMETYX launch in advanced NET capturing leading share, representing ~4% of Q2 CABOMETYX business.","Positive topline results from zanzalintinib STELLAR-303 study in colorectal cancer; plan to file for approval.","Early pipeline advancing: phase 1 trials for XL309, XB010, XB628; XB371 entering clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":1123708000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168207,"accession_number":"0000939767-25-000097","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Exelixis shareholders elect all 11 directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with strong majorities; broker non-votes of ~24M shares.","Ernst & Young ratified as auditor for FY ending Jan 2, 2026: 243M for, 6.4M against.","Advisory say-on-pay proposal approved: 218.9M for, 6.8M against, 24M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168206,"accession_number":"0000939767-25-000074","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q1 2025: Revenue $555.4M, GAAP EPS $0.55; raises FY2025 guidance by $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $555.4M (up 31% YoY); Cabozantinib U.S. net product revenues $513.3M (up 36% YoY).","GAAP diluted EPS $0.55 vs $0.12 in Q1 2024; Non-GAAP diluted EPS $0.62 vs $0.17.","Increasing 2025 full year net product revenues and total revenues guidance by $100M.","CABOMETYX launched in advanced NET after March FDA approval; initial reception positive.","Pipeline milestones: zanzalintinib pivotal readouts in CRC, nccRCC expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":555447000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185404,"accession_number":"0000939767-25-000049","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exelixis approves special PSU awards for all employees with $60 stock price performance goal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Michael Morrissey receives 589,719 shares of PSU; other NEOs receive between 132,819 and 170,009 shares.","Performance condition requires VWAP of $60 or more for 90 consecutive days within 5-year period.","Full vesting requires employment through fifth anniversary; forfeiture if stock price goal not met.","Program designed to align all employee interests with shareholder value creation over five years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185403,"accession_number":"0000939767-25-000032","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exelixis board authorizes additional $500M stock repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $500M authorization to be completed by Dec 31, 2025; current $500M program expected to finish in Q2 2025.","Fourth buyback program since March 2023; cumulative shareholder returns exceed $1.2B as of FY2024 end.","Repurchases may be executed via open market, block trades, ASR, or exchange transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185402,"accession_number":"0000939767-25-000017","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q4 2024 rev $567M, GAAP EPS $0.48; FY2024 rev $2.17B, EPS $1.76","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $566.8M for Q4 2024, up 18% YoY; FY2024 total rev $2.17B, up 18% YoY.","GAAP diluted EPS $0.48 (Q4 2024) vs $0.27 (Q4 2023); FY2024 $1.76 vs $0.65.","Non-GAAP diluted EPS $0.55 (Q4 2024) vs $0.33; FY2024 $2.00 vs $0.90.","Cabozantinib franchise U.S. net product revenues $515M (Q4), $1.81B (FY2024), up from $429M and $1.63B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":2168701000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185401,"accession_number":"0000939767-25-000004","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis announces preliminary FY2025 results and FY2026 guidance; audit pending","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Preliminary unaudited results for fiscal year ended Jan 3, 2025 provided in press release.","Financial guidance for fiscal year ending Jan 2, 2026 also included.","Audited financial results scheduled for release on February 11, 2025.","Business update delivered along with financial disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":2168701000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201988,"accession_number":"0000939767-24-000149","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exelixis Q3 revenue $539.5M, EPS $0.40; raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product revenue $478.1M (cabozantinib franchise) vs $426.5M YoY, +12%.","GAAP diluted EPS $0.40, non-GAAP diluted EPS $0.47; prior year $0.00 and $0.10.","Raises 2024 total revenue and net product revenue guidance on strong commercial performance.","Favorable U.S. District Court ruling on cabozantinib patent litigation received.","New collaboration with Merck adds two phase 3 trials for zanzalintinib in renal cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1601946000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201987,"accession_number":"0000939767-24-000140","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis wins patent case against MSN; generic launch blocked until Jan 2030","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Delaware court rejected MSN's invalidity challenges to three cabozantinib patents (11,091,439, 11,091,440, 11,098,015), all expiring Jan 15, 2030.","Court found MSN's ANDA product infringes those three patents; separate patent 11,298,349 (exp 2032) was not infringed.","Final judgment due Oct 22; FDA cannot approve MSN's generic before Jan 15, 2030 at the earliest.","Ruling protects Exelixis' cabozantinib franchise from generic entry for over five additional years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201986,"accession_number":"0000939767-24-000138","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis enters clinical collaboration with Merck for zanzalintinib combo trials in HNSCC and RCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration covers zanzalintinib + KEYTRUDA in phase 3 HNSCC trial (STELLAR-305) and zanzalintinib + WELIREG in RCC phase 1/2 and two phase 3 trials.","Merck supplies KEYTRUDA and sponsors one RCC phase 3; Exelixis co-funds phase 1/2 and other phase 3, supplies zanzalintinib and cabozantinib.","Exelixis retains all global commercial and marketing rights to zanzalintinib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218032,"accession_number":"0000939767-24-000116","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Exelixis Q2 revenue $637M, GAAP EPS $0.77; $500M buyback, FDA accepts cabozantinib sNDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $637.2M vs $469.8M YoY; cabozantinib U.S. net product revenues $437.6M.","GAAP diluted EPS $0.77 vs $0.25 YoY; non-GAAP diluted EPS $0.84 vs $0.31.","FDA accepted sNDA for cabozantinib in advanced NET; target action date April 3, 2025.","Earned $150M milestone from Ipsen; completed $450M buyback; new $500M buyback authorized through 2025.","Discontinued XB002 development; plans to initiate phase 3 for zanzalintinib in NET."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1062404000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237979,"accession_number":"0000939767-24-000081","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Exelixis stockholders approve ESPP share increase and elect directors at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved amendment to 2000 Employee Stock Purchase Plan, increasing authorized shares by 6 million.","Elected 11 directors to serve until 2025 annual meeting; all nominees received majority support.","Ratified Ernst & Young as independent auditor for fiscal year ending Jan 3, 2025; 254.6M votes for.","Advisory Say on Pay proposal approved with 226.7M votes for, 9.8M against.","Broker non-votes of 26.5M shares across director elections and other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237978,"accession_number":"0000939767-24-000074","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis settles CABOMETYX patent litigation; Cipla generic launch from Jan 1, 2031","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with Cipla resolves two Hatch-Waxman patent suits over CABOMETYX (cabozantinib).","Cipla receives license to market generic CABOMETYX in US starting January 1, 2031, if FDA approved.","All ongoing Delaware district court litigation will be dismissed pending FTC review.","Agreement confidential and subject to review by FTC and DOJ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237977,"accession_number":"0000939767-24-000062","cik":939767,"company_name":"EXELIXIS, INC.","ticker":"EXEL","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exelixis sues Cipla over generic Cabometyx patents covering 20mg, 40mg strengths","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Cipla amended its ANDA to seek approval for 20mg and 40mg generic cabozantinib, adding Paragraph IV certifications.","Exelixis filed a patent infringement complaint on May 9, 2024 in Delaware federal court.","Five patents asserted: U.S. Patent Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, 11,298,349.","Exelixis seeks order that FDA approval be no earlier than the latest patent expiration on February 10, 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12575294138.486397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}